{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:18:06Z","timestamp":1783034286348,"version":"3.54.6"},"reference-count":11,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Early recognition of patients at risk for radioactive iodine refractoriness (RAIR) is essential, as these individuals often face a poorer prognosis. Consequently, there is a pressing need for advanced therapeutic options in aggressive thyroid cancer cases. We present a case involving a 57-year-old male with prostate adenocarcinoma who, through prostate-specific membrane antigen (PSMA) PET\/CT scanning, was incidentally found to have a PSMA-avid lung nodule. Subsequent biopsy confirmed metastatic thyroid carcinoma. Following two sessions of radioactive iodine (RAI) therapy, posttherapy scans showed a noniodine-avid lung nodule. The PSMA-avid lung lesion indicates an aggressive disease form likely to develop RAI resistance, which was subsequently confirmed. This finding suggests that PSMA expression could be an effective early predictor of RAIR. Moreover, the PSMA avidity of these lesions supports the use of Lutetium-177-PSMA therapy, expanding treatment options for RAIR-differentiated thyroid carcinoma (DTC).<\/jats:p>","DOI":"10.1055\/s-0045-1812053","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T22:50:17Z","timestamp":1760050217000},"page":"161-163","source":"Crossref","is-referenced-by-count":0,"title":["A Case Report of Incidental Thyroid Cancer Metastasis Detected in a PSMA PET\/CT Scan of a Prostate Cancer Patient: Predicting RAI-Refractoriness"],"prefix":"10.1055","volume":"25","author":[{"given":"Isavelina F. C.","family":"Gries","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Theranostics, St. Luke's Medical Center, Global City, Metro Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo E. S.","family":"Ongkeko","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Theranostics, St. Luke's Medical Center, Global City, Metro Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E. A.","family":"Fernando","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Theranostics, St. Luke's Medical Center, Global City, Metro Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3803\/EnM.2015.30.4.543","article-title":"Risk factors for recurrence in Filipinos with well-differentiated thyroid cancer","volume":"30","author":"T EN Lo","year":"2015","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2214\/AJR.19.21084","article-title":"Gallium-68\u2013labeled prostate-specific membrane antigen\u201311 PET\/CT of prostate and nonprostate cancers","volume":"213","author":"S Osmany","year":"2019","journal-title":"AJR Am J Roentgenol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13550-020-00720-3","article-title":"Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study","volume":"10","author":"C Lawhn-Heath","year":"2020","journal-title":"EJNMMI Res"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/RLU.0000000000002161","article-title":"Evidence of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68GA-PSMA-HBED-CC PET\/CT","volume":"43","author":"P Verma","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.18632\/oncotarget.23984","article-title":"Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid","volume":"9","author":"B Heitk\u00f6tter","year":"2018","journal-title":"Oncotarget"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13550-019-0559-9","article-title":"PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome","volume":"9","author":"M Sollini","year":"2019","journal-title":"EJNMMI Res"},{"issue":"17","key":"ref7","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.3390\/cancers15174290","article-title":"Molecular theranostics in radioiodine-refractory differentiated thyroid cancer","volume":"15","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.117.195172","article-title":"Immunohistochemical validation of PSMA expression measured by 68GA-PSMA PET\/CT in primary prostate cancer","volume":"59","author":"N Woythal","year":"2018","journal-title":"J Nucl Med"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-022-10375-z","article-title":"Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy","volume":"22","author":"Y J Ryu","year":"2022","journal-title":"BMC Cancer"},{"issue":"12","key":"ref10","first-page":"3536","article-title":"PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome","volume":"106","author":"R Ciappuccini","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"794759","DOI":"10.3389\/fendo.2021.794759","article-title":"Head-to-head comparison of 68Ga-PSMA-11 and 131I in the follow-up of well-differentiated metastatic thyroid cancer: a new potential theragnostic agent","volume":"12","author":"Q Pitalua-Cortes","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1812053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:37:54Z","timestamp":1783031874000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1812053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":11,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,7,2]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1812053","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}